Flexible Eye Robot Could Reach Vessels Surgeons Cannot

A Flexible Eye Robot could soon help surgeons reach some of the smallest and most delicate blood vessels in the human body, after a major public research funder backed the next stage of its development. According to the Association of Optometrists, the project has received a grant worth more than two million pounds from the National Institute for Health and Care Research, and the money will support testing the system in patients for the first time.

The machine is designed for retinal surgery, where treatment must be delivered inside the eye with extraordinary precision. Its developers say the flexible design lets surgeons approach the retina from angles that a rigid instrument cannot manage, opening up routes to vessels that are currently out of practical reach. For people living with sight-threatening conditions, that flexibility could eventually mean treatments that are more targeted, less traumatic, and easier to repeat.

Why tiny vessels defeat even steady hands

The challenge is scale. Retinal blood vessels can be thinner than a human hair, and delivering medicine directly into one of them by hand demands a level of steadiness that pushes human dexterity to its limit. A small tremor, a slight change in angle, or a moment of fatigue can make the difference between a successful delivery and a missed target. Surgeons can compensate with training and experience, but the anatomy itself leaves almost no margin for error.

That limitation matters because several common eye diseases are driven by problems in those same vessels. Damage linked to diabetes can weaken and leak from retinal vessels over time, while a blockage in a retinal vein can cut off circulation and threaten central vision. Existing treatments often rely on injections into the eye, which can slow disease but must be repeated, and each visit carries its own burden for patients and clinics. A tool that could place medicine exactly where it is needed, inside the vessel itself, would change the calculation for doctors weighing benefit against risk.

Engineers have spent years trying to solve the access problem rather than simply asking surgeons to be steadier. The London university leading the work has previously explored continuum-style machines that bend like a trunk, flexing and changing shape to steer around critical structures while keeping the tip precisely controlled. According to the university research page, those systems are built to mimic the dexterity of a human hand while adding sensing and stability that no hand can match. The new funding takes that idea from the laboratory bench toward real clinical use.

What the new funding unlocks

The Flexible Eye Robot will be judged on the same practical questions that decide whether any surgical tool survives contact with real clinics. The grant will let the team test safety, usability, and performance in patients, according to the optometrists association report. That sequence matters: a device can work beautifully in a model eye and still fail in a clinic, where lighting, movement, time pressure, and individual anatomy all complicate the task. Patient testing will reveal whether surgeons can control the flexible instrument intuitively, whether the system behaves reliably across different eyes, and whether patients tolerate the procedure well.

The team will also expand what the machine can do, so that it can deliver drugs directly into retinal veins, and prepare the regulatory documentation that any medical device needs before wider use. Those two steps are often the slowest part of bringing a surgical innovation to patients, because regulators rightly demand evidence that a new tool is both safe and genuinely better than what already exists. The funding covers that unglamorous but essential groundwork alongside the clinical testing itself.

Professor Christos Bergeles, who leads surgical and interventional engineering research at the London university, described the project as the culmination of almost a decade of work across the partner institutions. The collaboration brings together the university, a world-famous London eye hospital, and a university in Kent, combining engineering, clinical insight, and surgical practice. That mix is deliberate: a robot designed by engineers alone might impress in a demonstration and disappoint in an operating theatre, while a tool designed by clinicians alone might never achieve the precision the task demands.

A decade in the making, and a field moving fast

The retinal robot is not arriving in isolation. Eye surgery has become a testing ground for precision robotics precisely because the stakes are so high and the working space so small. A separate purpose-built robotic system for radiotherapy to the back of the eye, developed by researchers at the same London university with hospital and university partners, was tested in a large trial involving more than four hundred participants across thirty hospitals. According to the Society of Radiographers, that system let clinicians aim overlapping beams at a very small lesion with remarkable precision, and better disease control could cut the number of eye injections some patients need by about a quarter.

The comparison is instructive. The radiotherapy system attacks disease from outside the eye with beams, while the new flexible machine works inside the eye to deliver treatment directly to vessels. Both share the same underlying bet: that machines can hold a position and a trajectory more steadily than a human hand, and that steadiness translates into better outcomes. Both also share the same hurdle, which is proving the benefit in real patients over time rather than in a single impressive demonstration.

For readers, the honest picture is one of promise without a promise of immediate access. The flexible system is still experimental, and patient testing is a beginning, not a finish line. Regulatory review, larger trials, training for surgical teams, and decisions about cost and availability will all take time, and some promising devices never clear those stages. Surgeons will also remain firmly in control: the robot is a tool that extends what a skilled clinician can do, not a replacement for judgement about who should be treated and when.

Still, the direction of travel is clear. As populations age, retinal disease is becoming more common, and clinics are already stretched by the volume of repeat injections and follow-up visits. A device that could deliver treatment more precisely, in fewer sessions, or to patients who currently have no good option would ease pressure on services as well as on individuals. That is why a grant for patient testing matters beyond the laboratory: it marks the moment when an engineering idea starts to answer the questions that patients actually ask, which are whether it is safe, whether it works, and when they might benefit. Readers following eye care should also note related progress in cheaper eye treatments reaching approval, alongside wider health advances such as earlier vaccination lifting teen coverage and research into brain changes linked to later disease risk.